- Home
- SNTG vs APVO Comparison
SNTG vs APVO Comparison
Compare SNTG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- APVO
- Stock Information
- Founded
- SNTG 2009
- APVO 2016
- Country
- SNTG China
- APVO United States
- Employees
- SNTG N/A
- APVO N/A
- Industry
- SNTG Finance: Consumer Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- APVO Health Care
- Exchange
- SNTG Nasdaq
- APVO Nasdaq
- Market Cap
- SNTG 4.8M
- APVO 4.1M
- IPO Year
- SNTG 2021
- APVO N/A
- Fundamental
- Price
- SNTG $1.81
- APVO $2.99
- Analyst Decision
- SNTG
- APVO Strong Buy
- Analyst Count
- SNTG 0
- APVO 1
- Target Price
- SNTG N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- SNTG 6.5K
- APVO 6.6M
- Earning Date
- SNTG 07-07-2025
- APVO 08-07-2025
- Dividend Yield
- SNTG N/A
- APVO N/A
- EPS Growth
- SNTG N/A
- APVO N/A
- EPS
- SNTG N/A
- APVO N/A
- Revenue
- SNTG $107,507.00
- APVO N/A
- Revenue This Year
- SNTG N/A
- APVO N/A
- Revenue Next Year
- SNTG N/A
- APVO N/A
- P/E Ratio
- SNTG N/A
- APVO N/A
- Revenue Growth
- SNTG N/A
- APVO N/A
- 52 Week Low
- SNTG $1.43
- APVO $2.81
- 52 Week High
- SNTG $3.97
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- SNTG 51.43
- APVO 33.78
- Support Level
- SNTG $1.67
- APVO $2.90
- Resistance Level
- SNTG $1.86
- APVO $13.11
- Average True Range (ATR)
- SNTG 0.09
- APVO 1.06
- MACD
- SNTG 0.00
- APVO 0.25
- Stochastic Oscillator
- SNTG 51.85
- APVO 2.62
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.